lidocaine hydrochloride + methylprednisolone: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
lidocaine hydrochloride + methylprednisolone: clinical details
Prescribing considerations
- Confirm an inflammatory indication and that a local-anaesthetic effect is advantageous; treatment is symptomatic rather than curative.
- Exclude local or systemic infection and assess joint fluid when bacterial infection is possible.
- Use precise anatomical localisation and sterile technique; avoid intravascular placement and injection into tendon substance.
- Review allergy history and assess diabetes, immune suppression, psychiatric history, visual disorders and relevant cardiovascular or neurological disease.
- Account for systemic methylprednisolone absorption and cumulative corticosteroid exposure.
Contraindications and cautions
- Hypersensitivity to methylprednisolone, lidocaine, another amide local anaesthetic or any excipient
- Systemic infection unless specific anti-infective treatment is being used
- Intrathecal, intravascular or intramuscular administration
- Live or live-attenuated vaccination during immunosuppressive corticosteroid exposure
Monitoring
- Observe for immediate hypersensitivity and neurological or cardiovascular signs of lidocaine toxicity.
- Monitor for infection, including atypical or masked presentations.
- Consider blood-glucose monitoring in diabetes and relevant monitoring for blood pressure, fluid balance and potassium disturbances.
- Assess new psychiatric or visual symptoms promptly.
- Consider adrenal suppression and other systemic corticosteroid effects with repeated, prolonged or combined corticosteroid exposure.
Clinical pharmacology
Methylprednisolone acetate is a depot synthetic glucocorticoid with anti-inflammatory and immunosuppressive activity. Lidocaine is an amide local anaesthetic that reversibly blocks nerve conduction. Pharmacokinetic studies have not been performed on the combined product, but systemic absorption can occur after intra-articular administration.
Formulation and product differences
- White sterile aqueous suspension for local injection.
- Single-dose vial; multidose use risks contamination.
- Contains benzyl alcohol as a preservative and is essentially sodium-free.
- Must not be mixed with another preparation because flocculation may occur.
- Not suitable for intravenous, intramuscular, intrathecal, intranasal or intraocular administration.
lidocaine hydrochloride + methylprednisolone interactions
Tell the clinician about all prescribed, over-the-counter and complementary products. Interactions can occur because methylprednisolone may be absorbed systemically.
Strong CYP3A inhibitors, including clarithromycin, itraconazole, ketoconazole, ritonavir and cobicistat
May increase methylprednisolone exposure and systemic corticosteroid adverse effects.
CYP3A inducers, including rifampicin, carbamazepine, phenytoin and phenobarbital
May increase corticosteroid metabolism and reduce its effect.
Warfarin and other vitamin K antagonists
The anticoagulant effect may increase or decrease, so closer clotting monitoring may be required.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.